Literature DB >> 27910851

CRISPR-Cas9-mediated multiplex gene editing in CAR-T cells.

Xiaojuan Liu1, Yongping Zhang2, Chen Cheng1,3, Albert W Cheng4, Xingying Zhang1,5, Na Li1, Changqing Xia2,6, Xiaofei Wei7, Xiang Liu1, Haoyi Wang1,5,8.   

Abstract

Mesh：

Substances：

Year:  2016        PMID： 27910851      PMCID： PMC5223227          DOI： 10.1038/cr.2016.142

Source DB:  PubMed          Journal:  Cell Res        ISSN： 1001-0602            Impact factor:   25.617


× No keyword cloud information.
  15 in total

1.  A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR.

Authors:  Hiroki Torikai; Andreas Reik; Pei-Qi Liu; Yuanyue Zhou; Ling Zhang; Sourindra Maiti; Helen Huls; Jeffrey C Miller; Partow Kebriaei; Brian Rabinovich; Brian Rabinovitch; Dean A Lee; Richard E Champlin; Chiara Bonini; Luigi Naldini; Edward J Rebar; Philip D Gregory; Michael C Holmes; Laurence J N Cooper
Journal:  Blood       Date:  2012-04-24       Impact factor: 22.113

Review 2.  Genome editing. The new frontier of genome engineering with CRISPR-Cas9.

Authors:  Jennifer A Doudna; Emmanuelle Charpentier
Journal:  Science       Date:  2014-11-28       Impact factor: 47.728

Review 3.  Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors.

Authors:  James N Kochenderfer; Steven A Rosenberg
Journal:  Nat Rev Clin Oncol       Date:  2013-04-02       Impact factor: 66.675

4.  Toward eliminating HLA class I expression to generate universal cells from allogeneic donors.

Authors:  Hiroki Torikai; Andreas Reik; Frank Soldner; Edus H Warren; Carrie Yuen; Yuanyue Zhou; Denise L Crossland; Helen Huls; Nicholas Littman; Ziying Zhang; Scott S Tykodi; Partow Kebriaei; Dean A Lee; Jeffrey C Miller; Edward J Rebar; Michael C Holmes; Rudolf Jaenisch; Richard E Champlin; Philip D Gregory; Laurence J N Cooper
Journal:  Blood       Date:  2013-06-05       Impact factor: 22.113

5.  Efficient ablation of genes in human hematopoietic stem and effector cells using CRISPR/Cas9.

Authors:  Pankaj K Mandal; Leonardo M R Ferreira; Ryan Collins; Torsten B Meissner; Christian L Boutwell; Max Friesen; Vladimir Vrbanac; Brian S Garrison; Alexei Stortchevoi; David Bryder; Kiran Musunuru; Harrison Brand; Andrew M Tager; Todd M Allen; Michael E Talkowski; Derrick J Rossi; Chad A Cowan
Journal:  Cell Stem Cell       Date:  2014-11-06       Impact factor: 24.633

6.  TALEN-Mediated Inactivation of PD-1 in Tumor-Reactive Lymphocytes Promotes Intratumoral T-cell Persistence and Rejection of Established Tumors.

Authors:  Laurie Menger; Anna Sledzinska; Katharina Bergerhoff; Frederick Arce Vargas; Julianne Smith; Laurent Poirot; Martin Pule; Javier Hererro; Karl S Peggs; Sergio A Quezada
Journal:  Cancer Res       Date:  2016-04-15       Impact factor: 12.701

7.  Generation of knock-in primary human T cells using Cas9 ribonucleoproteins.

Authors:  Kathrin Schumann; Steven Lin; Eric Boyer; Dimitre R Simeonov; Meena Subramaniam; Rachel E Gate; Genevieve E Haliburton; Chun J Ye; Jeffrey A Bluestone; Jennifer A Doudna; Alexander Marson
Journal:  Proc Natl Acad Sci U S A       Date:  2015-07-27       Impact factor: 11.205

8.  One-step generation of mice carrying mutations in multiple genes by CRISPR/Cas-mediated genome engineering.

Authors:  Haoyi Wang; Hui Yang; Chikdu S Shivalila; Meelad M Dawlaty; Albert W Cheng; Feng Zhang; Rudolf Jaenisch
Journal:  Cell       Date:  2013-05-02       Impact factor: 41.582

9.  CRISPR-Cas9 mediated efficient PD-1 disruption on human primary T cells from cancer patients.

Authors:  Shu Su; Bian Hu; Jie Shao; Bin Shen; Juan Du; Yinan Du; Jiankui Zhou; Lixia Yu; Lianru Zhang; Fangjun Chen; Huizi Sha; Lei Cheng; Fanyan Meng; Zhengyun Zou; Xingxu Huang; Baorui Liu
Journal:  Sci Rep       Date:  2016-01-28       Impact factor: 4.379

10.  Easy quantitative assessment of genome editing by sequence trace decomposition.

Authors:  Eva K Brinkman; Tao Chen; Mario Amendola; Bas van Steensel
Journal:  Nucleic Acids Res       Date:  2014-10-09       Impact factor: 16.971
View more
  97 in total

1.  Fluorescent labeling of CRISPR/Cas9 RNP for gene knockout in HSPCs and iPSCs reveals an essential role for GADD45b in stress response.

Authors:  Masoud Nasri; Perihan Mir; Benjamin Dannenmann; Diana Amend; Tessa Skroblyn; Yun Xu; Klaus Schulze-Osthoff; Maksim Klimiankou; Karl Welte; Julia Skokowa
Journal:  Blood Adv       Date:  2019-01-08

2.  CRISPR-Cas9 mediated LAG-3 disruption in CAR-T cells.

Authors:  Yongping Zhang; Xingying Zhang; Chen Cheng; Wei Mu; Xiaojuan Liu; Na Li; Xiaofei Wei; Xiang Liu; Changqing Xia; Haoyi Wang
Journal:  Front Med       Date:  2017-06-17       Impact factor: 4.592

Review 3.  Applications of genome editing technology in the targeted therapy of human diseases: mechanisms, advances and prospects.

Authors:  Hongyi Li; Yang Yang; Weiqi Hong; Mengyuan Huang; Min Wu; Xia Zhao
Journal:  Signal Transduct Target Ther       Date:  2020-01-03

Review 4.  Integrating Artificial Intelligence and Nanotechnology for Precision Cancer Medicine.

Authors:  Omer Adir; Maria Poley; Gal Chen; Sahar Froim; Nitzan Krinsky; Jeny Shklover; Janna Shainsky-Roitman; Twan Lammers; Avi Schroeder
Journal:  Adv Mater       Date:  2019-07-09       Impact factor: 30.849

5.  Regenerating Urethral Striated Muscle by CRISPRi/dCas9-KRAB-Mediated Myostatin Silencing for Obesity-Associated Stress Urinary Incontinence.

Authors:  Huixing Yuan; Yajun Ruan; Yan Tan; Amanda B Reed-Maldonado; Yinwei Chen; Dehua Zhao; Zhao Wang; Feng Zhou; Dongyi Peng; Lia Banie; Guifang Wang; Jihong Liu; Guiting Lin; Lei S Qi; Tom F Lue
Journal:  CRISPR J       Date:  2020-12

6.  TGF-β inhibition via CRISPR promotes the long-term efficacy of CAR T cells against solid tumors.

Authors:  Na Tang; Chen Cheng; Xingying Zhang; Miaomiao Qiao; Na Li; Wei Mu; Xiao-Fei Wei; Weidong Han; Haoyi Wang
Journal:  JCI Insight       Date:  2020-02-27

Review 7.  CRISPR Takes the Front Seat in CART-Cell Development.

Authors:  Claudia Manriquez-Roman; Elizabeth L Siegler; Saad S Kenderian
Journal:  BioDrugs       Date:  2021-02-27       Impact factor: 5.807

Review 8.  Next-generation regulatory T cell therapy.

Authors:  Leonardo M R Ferreira; Yannick D Muller; Jeffrey A Bluestone; Qizhi Tang
Journal:  Nat Rev Drug Discov       Date:  2019-09-20       Impact factor: 84.694

9.  CRISPR Technology for Breast Cancer: Diagnostics, Modeling, and Therapy.

Authors:  Rachel L Mintz; Madeleine A Gao; Kahmun Lo; Yeh-Hsing Lao; Mingqiang Li; Kam W Leong
Journal:  Adv Biosyst       Date:  2018-08-17

10.  The Future of Multiplexed Eukaryotic Genome Engineering.

Authors:  David B Thompson; Soufiane Aboulhouda; Eriona Hysolli; Cory J Smith; Stan Wang; Oscar Castanon; George M Church
Journal:  ACS Chem Biol       Date:  2017-12-28       Impact factor: 5.100
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.